Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Accounts Payables (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Accounts Payables readings, the most recent being $1.7 million for Q4 2025.

  • Quarterly Accounts Payables fell 19.88% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 19.88% year-over-year, with the annual reading at $1.7 million for FY2025, 19.88% down from the prior year.
  • Accounts Payables hit $1.7 million in Q4 2025 for Terns Pharmaceuticals, down from $2.9 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.5 million in Q2 2023 and bottomed at $973000.0 in Q2 2022.
  • Average Accounts Payables over 5 years is $2.4 million, with a median of $2.1 million recorded in 2021.
  • The largest annual shift saw Accounts Payables soared 469.06% in 2023 before it crashed 66.17% in 2024.
  • Terns Pharmaceuticals' Accounts Payables stood at $2.1 million in 2021, then dropped by 22.62% to $1.6 million in 2022, then surged by 52.89% to $2.5 million in 2023, then decreased by 14.59% to $2.1 million in 2024, then fell by 19.88% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Accounts Payables are $1.7 million (Q4 2025), $2.9 million (Q3 2025), and $2.8 million (Q2 2025).